Shares of Ziopharm Oncology Inc. (NASDAQ:ZIOP) dropped 5% on Tuesday . The company traded as low as $4.73 and last traded at $4.74, with a volume of 2,805,878 shares traded. The stock had previously closed at $4.99.

ZIOP has been the subject of a number of recent analyst reports. Wells Fargo & Co. reissued a “sell” rating on shares of Ziopharm Oncology in a research report on Thursday, May 19th. Vetr cut Ziopharm Oncology from a “strong-buy” rating to a “buy” rating and set a $9.76 price objective for the company. in a research report on Monday, April 18th. Zacks Investment Research cut Ziopharm Oncology from a “buy” rating to a “hold” rating in a research report on Tuesday, May 31st. Griffin Securities reaffirmed a “buy” rating and set a $21.00 price target on shares of Ziopharm Oncology in a research report on Friday, July 1st. Finally, Mizuho lifted their price target on Ziopharm Oncology from $6.00 to $7.00 and gave the stock a “neutral” rating in a research report on Wednesday, May 11th. One research analyst has rated the stock with a sell rating, four have given a hold rating, one has issued a buy rating and one has given a strong buy rating to the stock. The company has a consensus rating of “Hold” and an average target price of $10.57.

The company has a 50 day moving average price of $6.07 and a 200 day moving average price of $6.91. The stock’s market capitalization is $614.62 million.

Ziopharm Oncology (NASDAQ:ZIOP) last posted its quarterly earnings data on Tuesday, May 10th. The biotechnology company reported ($0.09) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.08) by $0.01. During the same quarter in the prior year, the company earned ($0.69) earnings per share. The firm earned $1.97 million during the quarter, compared to analyst estimates of $1.89 million. The company’s revenue for the quarter was up 623.9% on a year-over-year basis. Equities analysts forecast that Ziopharm Oncology Inc. will post ($0.42) earnings per share for the current year.

Several hedge funds recently bought and sold shares of the company. California State Teachers Retirement System raised its stake in Ziopharm Oncology by 1.6% in the fourth quarter. California State Teachers Retirement System now owns 212,521 shares of the biotechnology company’s stock worth $1,766,000 after buying an additional 3,354 shares in the last quarter. Swiss National Bank raised its stake in Ziopharm Oncology by 2.2% in the fourth quarter. Swiss National Bank now owns 159,220 shares of the biotechnology company’s stock worth $1,323,000 after buying an additional 3,500 shares in the last quarter. California Public Employees Retirement System raised its stake in Ziopharm Oncology by 567.2% in the fourth quarter. California Public Employees Retirement System now owns 307,366 shares of the biotechnology company’s stock worth $2,554,000 after buying an additional 261,300 shares in the last quarter. Finally, Morgan Stanley raised its stake in Ziopharm Oncology by 5.1% in the fourth quarter. Morgan Stanley now owns 1,618,205 shares of the biotechnology company’s stock worth $13,447,000 after buying an additional 78,583 shares in the last quarter.

ZIOPHARM Oncology, Inc is a biopharmaceutical company. The Company is seeking to acquire, develop and commercialize, on its own or with partners, a portfolio of cancer therapies through synthetic immuno-oncology. Its clinical-stage product candidate, Ad-RTS-IL-12, is used with the oral activator veledimex.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.